Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05352828
Title Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy (ACTION)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Tessa Therapeutics

Hodgkin's lymphoma


Bendamustine + Fludarabine

ATLCAR.CD30 cells + Nivolumab

Age Groups: senior | adult | child
Covered Countries USA

No variant requirements are available.